[Current status of continuous subcutaneous insulin infusion and continuous glucose monitoring systems in the Community of Madrid].
OBJECTIVE
To analyze the available information about continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems in the public health care system of the Community of Madrid.


METHODS
A survey consisting of 31 items was sent to the 28 endocrinology department of the Madrid public hospitals. Items focused on CSII and CGM and included patients' registrations, as well as data regarding healthcare, administrative, and logistic aspects. Responses from a total of 20 hospitals where these procedures are used were received from March 2013 to May 2014. Data about pediatric patients were obtained from adult endocrinology departments, except for two hospitals which directly reported the information.


RESULTS
A total of 1256 CSII pumps were recorded in the Madrid region, of which 1089 were used by adults, and the remaining 167 by pediatric patients. During 2013, 151 new CSII systems were implanted (12% of the total), while 14 pumps were withdrawn. Availability of human resources (medical assistance) and the number of staff practitioners experienced in management of these systems widely varied between hospitals. Eighty-five percent of hospitals used retrospective CGM systems, and 40% routinely placed them before starting an insulin pump. Thirteen hospitals (65%) used long-term, real-time CGM systems in selected cases (a total of 67 patients).


CONCLUSIONS
Use of these technologies in diabetes is unequal between public health care hospitals in Madrid, and is still significantly lower as compared to other countries with similar incomes. However, there appears to be a trend to an increase in their use.
Servicio de Endocrinología y Nutrición, Hospital Universitario de la Princesa, Madrid, España. Electronic address: alfonso.arranz@salud.madrid.org.
Alfonso
A
Arranz Martín
Servicio de Endocrinología y Nutrición, Hospital Universitario Clínico de San Carlos, Madrid, España.
Alfonso
A
Calle Pascual
Servicio de Endocrinología y Nutrición, Hospital Universitario Infanta Leonor, Madrid, España.
Francisco Javier
FJ
Del Cañizo Gómez
Servicio de Endocrinología y Nutrición, Hospital General Universitario Gregorio Marañón, Madrid, España.
Olga
O
González Albarrán
Servicio de Endocrinología y Nutrición, Hospital Central de la Defensa, Madrid, España.
Arturo
A
Lisbona Gil
Servicio de Endocrinología y Nutrición, Hospital Universitario Príncipe de Asturias, Madrid, España.
Marta
M
Botella Serrano
Servicio de Endocrinología y Nutrición, Hospital Universitario de La Paz, Madrid, España.
Luis Felipe
LF
Pallardo Sánchez
D000328:Adult; D015190:Blood Glucose Self-Monitoring / Q000706:statistics & numerical data*; D002648:Child; D003199:Computer Systems; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D019538:Health Care Surveys; D006779:Hospitals, Public / Q000706:statistics & numerical data; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D055104:Infusions, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000627:therapeutic use; D007332:Insulin Infusion Systems / Q000706:statistics & numerical data*; D013030:Spain; D011795:Surveys and Questionnaires
D007004:Hypoglycemic Agents; D007328:Insulin
Continuous glucose monitoring; Continuous subcutaneous insulin infusion; Diabetes mellitus tipo 1; Infusión subcutánea continua de insulina; Monitorización continua de glucosa; Type 1 diabetes mellitus